Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

10:17
10/11/16
10/11
10:17
10/11/16
10:17

Horizon Pharma guidance cut only a modest negative, says BMO Capital

BMO Capital analyst Gary Nachman said he views the pre-announced 3Q revenue and EBITDA shortfalls and full-year guidance cut announced by Horizon Pharma as only a modest negative, as he believes some investors were already cautious on guidance and that it was paired with good news about the company spending more to drive long-term growth. The analyst, who still thinks the Actimmune FA Phase 3 data coming in late December can be a major catalyst, keeps his Outperform rating and $30 price target on Horizon shares.

  • 14

    Dec

HZNP Horizon Pharma
$19.52

0.79 (4.22%)

08/02/16
BMOC
08/02/16
NO CHANGE
BMOC
Outperform
Horizon Pharma scored 'important win' with CVS, says BMO Capital
BMO Capital analyst Gary Nachman said Horizon Pharma (HZNP) securing covered status for Duexis and Vimovo with CVS/Caremark (CVS) is an "important win" for the drugmaker that demonstrates it is improving its execution on the managed care front. While Express Scripts (ESRX) still has Duexis and Vimovo on its exclusion list for 2017, Horizon indicated that it is still in discussions that have been "constructive," noted Nachman, who keeps an Outperform rating on Horizon shares.
09/13/16
BMUR
09/13/16
NO CHANGE
Target $32
BMUR
Buy
Horizon Pharma acquisition a positive, says Brean Capital
Brean Capital analyst Difei Yang said she is positive on Horizon Pharma's (HZNP) deal for Raptor Pharmaceuticals (RPTP). The analyst cited Horizon executing on its transformative strategy into an orphan disease company, the reasonable price paid for the company, and the moderate growth opportunities for synergies between the two. Yang reiterated her Buy rating and raised her price target to $32 from $30 on Horizon Pharma shares.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Horizon Pharma patent loss immaterial, says JMP Securities
After the U.S. Patent and Trademark Office ruled that Horizon Pharma's '215 patent for Ravicti is unpatentable, JMP Securities analyst Donald Ellis says the news is not material. He says that Ravicti still has orphan drug exclusivity until 2020, and that the company has five other patents on the drug that will last until 2032. He recommends buying Horizon on any weakness.
10/03/16
BMOC
10/03/16
NO CHANGE
BMOC
Horizon Pharma added to US Small Cap Fundamental List at BMO Capital

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.